Governance at
the Threshold
A MASTER’S THESIS
ESCP BUSINESS SCHOOL

ONE THESIS. TWO WAYS IN.

One question.
Two worlds.

Are biotech firms with more investor directors at IPO acquired sooner?

The research in one minute ↗︎The question, finding and important caveat.
Go straight to results
01 / THE RESEARCH
THE SEATS.
THE STAKES.
THE PLOT TWIST.
Scrooge McDuck welcoming visitors beside an open treasury vault

Follow the money.

Six chapters. Two reading modes. Eight optional questions.

Explore the research
02 / BEHIND THE SCENES
A playful research lab with a coin-filled flask, charts and lab notesA little data.
A lot of discovery.

Explore The Footnotes.

Research notes from behind the scenes. The decisions, corrections and questions behind the thesis.

Go behind the scenes

Pick either world. You can move between them whenever curiosity calls.

ABOUT THE RESEARCH

Frequently asked questions

Why study companies that listed between 2015 and 2021?

This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.

Why use SEC filings?

They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.

Why study listed companies rather than private ones?

The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.

Read all 24 questions